Introduction
Infantile hemangiomas (IHs) are the most common benign tumors of infancy[1], and the incidence ranges from 4% to 5%. They are more common in females and Caucasians, and are associated with low birth weight and prematurity of infants. Although IHs are benign and regress spontaneously[2], significant morbidity and mortality can occur during any phase, in particular during the proliferative phase of tumors. Intervention is indicated if the IHs are expected to cause morbidities.
屈园园 康晓静. A case of infantile hemangioma treated by various methods[J]. 国际皮肤性病学杂志, 2018, 1(4): 249-250.
Yuan-Yuan Qu, Xiu-Juan Wu, Xiao-Jing Kang*. A case of infantile hemangioma treated by various methods. International Journal of Dermatology and Venereolo, 2018, 1(4): 249-250.
CJF S, Friedlander SF, Guma M, et al. Infantile Hemangiomas: An updated review on risk factors, pathogenesis, and treatment. Birth Defects Res, 2017,109(11):809-15. doi:10.1002/bdr2.1023.
2. Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics, 2008,122(2):360-7. doi:10.1542/peds.2007-2767.
3. Andersen IG, Rechnitzer C, Charabi B. Effectiveness of propanolol for treatment of infantile haemangioma. Dan Med J, 2014,61(2):A4776.
4. Grzesik P, Wu JK. Current perspectives on the optimal management of infantile hemangioma. Pediatric Health Med Ther, 2017,8:107-16. doi:10.2147/PHMT.S115528.
5. Hogeling M, Adams S,Wargon D. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011;128(2):e259-66.
6. Couto JA, Greene AK. Management of problematic infantile hemangioma using intralesional triamcinolone: efficacy and safety in 100 infants. J Plast Reconstr Aesthet Surg, 2014,67(11):1469-74. doi:10.1016/j.bjps.2014.07.009.
7. Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol, 2010,163(2):269-74. doi:10.1111/j.1365-2133.2010.09848.x.
2018, Vol. 1 
